Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.
Term
Q3 2026
“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”
Cameron Turtle, DPhil, Chief Executive Officer of Spyre
Spyre Therapeutics reported a significant increase in its financial position, with total current assets growing from $777.8 million at the end of 2025 to approximately $1.1 billion as of September 30, 2026, primarily driven by an increase in marketable securities. The company is advancing its clinical pipeline, including the SKYLINE and SKYLIGHT Phase 2 trials, while maintaining a large accelerated filer status.
Spyre Therapeutics entered into an underwriting agreement for a public offering of 4,117,648 shares of common stock at $85.00 per share, expected to raise gross proceeds of approximately $350.0 million. The company intends to use the proceeds to advance its clinical programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and a new program for hidradenitis suppurativa.
Value
$350M
Counterparty
Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated
Spyre Therapeutics Insider Heidy King-Jones Sells $2.63M of Stock
Heidy King-Jones sold 28,933 shares of Spyre Therapeutics, Inc. at $89.24 to $93.46 a share (average $91.03) in 5 transactions, worth $2.63M in total on Oct 1, 2026. Shares held after the trade: 2,845 (-47.8%).
Spyre Therapeutics CEO Cameron Turtle Sells $1.37M of Stock
Cameron Turtle, CEO, sold 14,900 shares of Spyre Therapeutics, Inc. at $89.14 to $93.37 a share (average $91.99) in 5 transactions, worth $1.37M in total on Oct 1, 2026. Shares held after the trade: 537,640 (-0.9%).
Spyre Therapeutics CFO Scott L. Burrows Sells $2.26M of Stock
Scott L. Burrows, CFO, sold 25,000 shares of Spyre Therapeutics, Inc. at $89.07 to $93.57 a share (average $90.47) in 6 transactions, worth $2.26M in total between Sep 30, 2026 and Oct 1, 2026. Shares held after the trade: 79,762 (-0.3%).